
Ben Park, M.D., Ph.D.
- Director, Vanderbilt-Ingram Cancer Center
- Benjamin F. Byrd, Jr. Chair in Oncology
- Professor of Medicine (Hematology/Oncology)
777 Preston Research Building
2220 Pierce Ave
Nashville, TN 37232-6307
Ben Park, M.D., Ph.D.
- Director, Vanderbilt-Ingram Cancer Center
- Benjamin F. Byrd, Jr. Chair in Oncology
- Professor of Medicine (Hematology/Oncology)
ben.h.park@vumc.org
777 Preston Research Building
2220 Pierce Ave
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Ben Ho Park, MD, PhD, is Director of the Vanderbilt-Ingram Cancer Center (VICC). Dr. Park is also a Professor of Medicine in the Department of Medicine's Division of Hematology and Oncology.
Dr. Park's research is dedicated to finding a cure for all types of breast cancer by investigating mutated and altered genes responsible for the development and progression of breast cancer, as well as genes that lead to drug resistance. He is actively involved with the VICC Breast Cancer Research Program’s clinical research team to translate his research into clinical practice and patient care.
Dr. Park received his undergraduate degree with honors from the University of Chicago in 1989. He then completed a dual M.D., Ph.D. training program at the University of Pennsylvania School of Medicine in 1995. Dr. Park completed a residency in Internal Medicine and Hematology/Oncology Fellowship training at the Hospital of the University of Pennsylvania. In 2001, Dr. Park finished a postdoctoral research fellowship in cancer genetics in the laboratory of Dr. Bert Vogelstein at Johns Hopkins. In 2002, Dr. Park joined the faculty in the Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and held several positions including Associate Dean for Postdoctoral Affairs for the School of Medicine and Associate Director for Research Training and Education for the Johns Hopkins Cancer Center. Dr. Park joined Vanderbilt University Medical Center/Vanderbilt University in 2018.
Education
- M.D., University of Pennsylvania, Philadelphia, Pennsylvania (1995)
- Ph.D., University of Pennsylvania, Philadelphia, Pennsylvania (1995)
- A.B., University of Chicago, Chicago, Illinois (1989)
Postgraduate Training
- Internal Medicine Residency, University of Pennsylvania
- Heme/Onc Fellowship, University of Pennsylvania
- Cancer Genetics Postdoctoral Fellowship, Johns Hopkins University
Research Emphasis
Research Description
Publications
- Karthikeyan S, Park BH. Circulating Tumor DNA as a Marker for Disease Relapse in Early-Stage Breast Cancer-Bad Blood. JAMA Oncol [print-electronic]. 2019 Aug 8/1/2019; PMID: 31369044, PII: 2740688, DOI: 10.1001/jamaoncol.2019.2047, ISSN: 2374-2445.
- Zhang X, Wang Y, Chiang HC, Hsieh YP, Lu C, Park BH, Jatoi I, Jin VX, Hu Y, Li R. BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. Breast Cancer Res. 2019 Apr 4/17/2019; 21(1): 51. PMID: 30995943, PMCID: PMC6472090, PII: 10.1186/s13058-019-1132-1, DOI: 10.1186/s13058-019-1132-1, ISSN: 1465-542X.
- Button B, Croessmann S, Chu D, Rosen DM, Zabransky DJ, Dalton WB, Cravero K, Kyker-Snowman K, Waters I, Karthikeyan S, Christenson ES, Donaldson J, Hunter T, Dennison L, Ramin C, May B, Roden R, Petry D, Armstrong DK, Visvanathan K, Park BH. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies. Breast Cancer Res. Treat [print-electronic]. 2019 Apr; 174(2): 401-12. PMID: 30560461, PMCID: PMC6447053, PII: 10.1007/s10549-018-05087-7, DOI: 10.1007/s10549-018-05087-7, ISSN: 1573-7217.
- Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J. Clin. Oncol [print-electronic]. 2019 Mar 3/20/2019; 37(9): 714-22. PMID: 30721110, PMCID: PMC6424139, DOI: 10.1200/JCO.2018.78.7986, ISSN: 1527-7755.
- Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res. Treat [print-electronic]. 2018 Sep 9/28/2018; PMID: 30267249, PII: 10.1007/s10549-018-4921-9, DOI: 10.1007/s10549-018-4921-9, ISSN: 1573-7217.
- Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2015 Nov 11/10/2015; 112(45): E6205-14. PMID: 26508629, PMCID: PMC4653184, PII: 1516853112, DOI: 10.1073/pnas.1516853112, ISSN: 1091-6490.
- Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Mol. Cell Proteomics [print-electronic]. 2015 Jul; 14(7): 1959-76. PMID: 25953087, PMCID: PMC4587316, PII: M115.049783, DOI: 10.1074/mcp.M115.049783, ISSN: 1535-9484.